What a Mounjaro course actually looks like from first pen to last

You've collected your first pen, here's what the next few months look like

Picture this: the box arrives in plain packaging on a Tuesday morning. Inside is a KwikPen pre-loaded with 2.5 mg tirzepatide. Your instinct might be to wonder whether such a small dose is doing anything. It isn't supposed to, not yet. The 2.5 mg starting strength exists to let your gut adjust to a GLP-1 and GIP receptor agonist before the dose does any heavy lifting. Nausea, if it appears at all, is typically most noticeable in the days after starting or stepping up, and it usually settles within one to two weeks as your body adapts.

After four weeks at 2.5 mg, your prescriber reviews your progress. If you are tolerating the medicine well, the next pen will be 5 mg. The licensed pathway continues in 2.5 mg steps (7.5, 10, 12.5, up to 15 mg) with each level held for at least four weeks before any increase. The tirzepatide prescribing pathway is not a race to the top dose; some people find their sweet spot at 7.5 mg or 10 mg and stay there. That is a clinical call, not a failing. The SURMOUNT-1 trial, published in the New England Journal of Medicine, ran for 72 weeks and showed average weight reductions of around 20–21% at 15 mg, those results came from sustained, properly titrated treatment over many months, not from the first pen.

One practical note on timing: if your order falls near a bank holiday or you are planning to travel, it is worth factoring in the titration schedule when you next reorder, so a delay doesn't leave you holding a higher dose you're not yet approved for.

What a Mounjaro course demands of you between injections

The injection itself takes seconds. The course, though, is built around what happens in the other six days and twenty-three hours of the week. Clinical trials paired tirzepatide with a reduced-calorie diet and increased physical activity, and that pairing matters. The medicine reshapes appetite (most people describe eating noticeably less without feeling deprived) but building habits around adequate protein, regular movement and staying hydrated gives those changes somewhere to go. Our frequently asked questions cover a lot of the day-to-day detail that patients raise once they're mid-course.

Progress tracking is part of the course too. How often you weigh yourself matters more than people realise: too frequently and normal daily fluctuation becomes demoralising noise; too rarely and you miss early signals worth discussing with your prescriber. Monthly weighing, or fortnightly at most, tends to give a clearer picture. Weight loss on a properly titrated course is rarely linear, plateaus are common, especially after a particularly productive early phase.

Common side effects across a course are predominantly gastrointestinal: nausea, loose stools, constipation, reflux and burping appear on the list. These are detailed on the NHS tirzepatide page, and they tend to be most pronounced at the point of a dose increase before fading. Serious side effects are rare; the MHRA flagged acute pancreatitis as a known but infrequent risk in a 2026 Drug Safety Update, so severe or persistent stomach pain that spreads to the back needs prompt medical attention.

How long the course runs and what happens at the end

There is no single universally prescribed length. NICE's appraisal of tirzepatide (TA1026) recommends that continuing treatment is reviewed if less than 5% of body weight has been lost after six months at the highest tolerated dose. That review is not an automatic stop, it is a conversation about whether ongoing treatment is appropriate for you. For those who respond well, courses can run for a year or more.

The question of what happens at the end is one patients often raise partway through. Stopping tirzepatide is its own topic worth reading about before you get there. The short version is that gradual reduction under clinical guidance is generally preferred over an abrupt stop, and plans for maintaining progress through diet and activity need to be in place before the final pen. Equally, there is no arbitrary finishing line, some people continue indefinitely where the clinical picture supports it.

If you want to understand the full cost picture before committing to a course, the Mounjaro cost page lays out what private treatment typically involves in the UK market, and what a transparent price should include. At nume, each repeat order is clinically reviewed before it is dispensed, there are no auto-renewals, no subscription you need to remember to cancel.

Starting a course through a regulated online pharmacy

The only legal route to tirzepatide in the UK is a prescription issued after clinical assessment. For people who don't meet the current NHS eligibility thresholds (or who prefer not to join a waiting list) a regulated online pharmacy is the private alternative. Not all are equivalent. The GPhC publishes a publicly searchable pharmacy register where any registered UK pharmacy can be verified; that check takes under a minute and is worth doing before handing over payment or medical details.

At nume, every consultation is read by a named prescriber on the same day, a real clinician, not a form-sorter. Identity and current weight are confirmed before any prescription is issued. If you are transferring from another provider mid-course, we ask for evidence of your current dose; we don't just dispense the next pen on your say-so. That matters for safety, not bureaucracy. Clinicians and healthcare professionals looking to support patients through this treatment can also find out more through our Mounjaro training course for UK practitioners. You can read more about Mounjaro at nume or explore weight-loss treatment options more broadly if you're still deciding. When you're ready, speak to our prescribers through a free consultation, no commitment required to ask.